Clinical Trials

Brief Overview:

Patients with a new diagnosis of brain tumor will undergo surgical removal. If the pathology reveals glioblastoma multiforme, the patient will be eligible to continue. After surgery, patients will undergo a procedure to harvest white blood cells from their bodies. These cells will be combined with tissue for the tumor surgery to create a vaccine. Patients will randomly be placed into two groups: Group A will receive standard therapy with radiation and chemotherapy as well as vaccine injections. Group B will recieve standard therapy with radiation and chemotherapy as well as placebo injections. Group B will have the opportunity to recieve the vaccine at a later date.
Inclusion Criteria
- At least 18 to less than 70 years of age
- Good neurologic performance status

Exclusion Criteria
- History of prior malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or other cancers that were deemed fully resolved 10 or more years prior to study
- History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, scleroderma, polymyositis-dermatomyositis, juvenile onset insulin dependent diabetes, or vasculitis
- Implantation of Gliadel wafers at surgery